Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation

EuroIntervention. 2016 Feb;11(10):1180-7. doi: 10.4244/EIJY15M02_05.

Abstract

Aims: To describe the characteristics of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI).

Methods and results: This study was performed using the GAMES database, a national prospective registry of consecutive patients with IE in 26 Spanish hospitals. Of the 739 cases of IE diagnosed during the study, 1.3% were post-TAVI IE, and these 10 cases, contributed by five centres, represented 1.1% of the 952 TAVIs performed. Mean age was 80 years. All valves were implanted transfemorally. IE appeared a median of 139 days after implantation. The mean age-adjusted Charlson comorbidity index was 5.45. Chronic kidney disease was frequent (five patients), as were atrial fibrillation (five patients), chronic obstructive pulmonary disease (four patients), and ischaemic heart disease (four patients). Six patients presented aortic valve involvement, and four only mitral valve involvement; the latter group had a higher percentage of prosthetic mitral valves (0% vs. 50%). Vegetations were found in seven cases, and four presented embolism. One patient underwent surgery. Five patients died during follow-up: two of these patients died during the admission in which the valve was implanted.

Conclusions: IE is a rare but severe complication after TAVI which affects about 1% of patients and entails a relatively high mortality rate. IE occurred during the first year in nine of the 10 patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aortic Valve Stenosis / surgery*
  • Endocarditis / therapy*
  • Endocarditis, Bacterial / epidemiology*
  • Female
  • Heart Valve Prosthesis
  • Heart Valve Prosthesis Implantation* / methods
  • Humans
  • Incidence
  • Male
  • Prospective Studies
  • Prosthesis-Related Infections / epidemiology*
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome